BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25475380)

  • 1. Radionuclide therapy for osseous metastases in prostate cancer.
    Abi-Ghanem AS; McGrath MA; Jacene HA
    Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
    Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
    Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
    Cheetham PJ; Petrylak DP
    Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
    Bruland ØS; Nilsson S; Fisher DR; Larsen RH
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6250s-6257s. PubMed ID: 17062709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 Therapy of Bone Metastases in Prostate Cancer.
    Nilsson S
    Semin Nucl Med; 2016 Nov; 46(6):544-556. PubMed ID: 27825434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
    Bertolaso P; Leroy L; Gross-Goupil M; Aupee O; Ravaud A; Roubaud G; Cazeau AL; Le Moulec S
    Bull Cancer; 2017 Sep; 104(9):762-770. PubMed ID: 28797482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-targeting radiopharmaceuticals including radium-223.
    Brady D; Parker CC; O'Sullivan JM
    Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.
    Lewis B; Chalhoub E; Chalouhy C; Sartor O
    Oncology (Williston Park); 2015 Jul; 29(7):483-8. PubMed ID: 26178336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.
    Patel CM; Wadas TJ; Shiozawa Y
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33918705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 dichloride for the treatment of metastatic prostate cancer.
    Turner PG; O'Sullivan J
    Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radium-223 for the treatment of prostate cancer.
    Hafeez S; Parker C
    Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
    Pandit-Taskar N; Larson SM; Carrasquillo JA
    J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Palliative treatment of bone metastases with bone-seeking radionuclides].
    De Klerk JM; Zonnenberg BA; Huiskes AW; Han SH; Blijham GH; Van Rijk PP
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2618-22. PubMed ID: 10028362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival.
    Rove KO; Crawford ED
    Oncology (Williston Park); 2011 Dec; 25(14):1362-70, 1375-81, 1387. PubMed ID: 22329188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.
    Liepe K
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1346-58. PubMed ID: 19943206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
    Pandit-Taskar N; Batraki M; Divgi CR
    J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation for bone metastases.
    Bourgeois DJ; Kraus S; Maaloof BN; Sartor O
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):227-32. PubMed ID: 21734581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.